Table 1.
Summary of characteristics of included studies investigating HMGB1 and RAGE
| Study | Neoplasm | Sample | N (total) | N (malignant) | Mean Age (range) | Gender M : F |
|---|---|---|---|---|---|---|
| Court et al. (2004) | AML | Bone marrow | 18 | 11 | 64a (21–75) | – |
| Xu et al. (2004) | ALL | Bone marrow | 28 | 28 | - | – |
| Meyer et al. (2008) | NHLb | FFPE | 24 | 18 | 50.9 (17–87) | 8 : 6* |
| Zappasodi et al. (2010) | BCL | Lymphoma cells from LN or blood | 14 | 14 | 58.2 (45–72) | 10 : 4 |
| Nomura et al. (2011) | Various | Serum | 45 | 45 | 54a (21–78) | 27 : 18 |
| Mao et al. (2012) | T cell lymphoma | FFPE biopsy | 142 | 102 | 56 (14–81) | 60 : 42 |
| Inoue et al. (2013) | Variousc | Serum | 54 | 54 | 61a (26–77) | 32 : 22 |
| Jia et al. (2014) | CLL | Plasma & FFPE LN biopsy | 60 (plasma) 144 (LN) | 60 (plasma) 86 (LN) | – | – |
| Kimura et al. (2014) | Adult ATLL | Plasma | 13 | 8 | ||
| Lu et al. (2014) | AML | Bone marrow aspirate | 43 | 43 | 46a (13–80) | 20 : 23 |
Not all reported.
Median.
DLBCL (n = 8), anaplastic large T cell lymphoma (n = 1), follicular lymphoma (n = 6), small lymphocytic lymphoma (n = 2), nodal marginal zone BCL (n = 1).
AML (n = 18), ALL (n = 5), DLBCL (n = 7), follicular lymphoma (n = 5), angioimmunoblastic T cell lymphoma (n = 1), myelodysplastic syndrome (n = 8), multiple myeloma (n = 5), ATLL (n = 1), complicated hematopoietic stem cell transplant patient (n = 4).
ALL – acute lymphocytic leukemia; AML – acute myeloid leukemia; ATLL – acute T cell leukemia/lymphoma; BCL – B cell lymphoma; CLL – chronic lymphocytic leukemia; DLBCL – diffuse large B cell lymphoma; FFPE – formalin-fixed paraffin-embedded; NHL – non-Hodgkin lymphoma